2015. XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis. Acta Medica Philippina. 49, 2 (Jun. 2015). DOI:https://doi.org/10.47895/amp.v49i2.988.